Inve India ▾

Poly Medicure share price & results

Poly Medicure Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Indian medical-device maker spanning infusion, renal, cardiology and orthopaedics; sold in 125+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue525 ₹ crore+30.3% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin24.0 %−2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit85.0 ₹ crore−8.6% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity10.90 %−4.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-3.15 %+2.7 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)18.36 %−9.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 of 10 judged targets kept · 20 open · verdicts reflect calls analysed to Q1 FY27.

Poly Medicure Limited management guidance track record on Inve: 30 targets tracked across analysed earnings calls (5 achieved, 5 missed, 20 open).

TargetOriginal wordingSaidLatest callVerdict
H2 FY26 Revenue₹1,080 - ₹1,090 crores
Call transcript, Q2 FY26 · 10 Nov 2025		Q2 FY26Q1 FY27:Promise pertains to FY26 and is complete.
Call transcript, Q1 FY27 · 10 Aug 2026		Achieved*
Consolidated Revenue Growth FY2620%
Call transcript, Q4 FY25 · 7 May 2025		Q4 FY25Q1 FY27:Promise pertains to FY26 and is complete.
Call transcript, Q1 FY27 · 10 Aug 2026		Missed
Long-term Revenue Growthnew normal for this Company should be 20% plus growth
Call transcript, Q3 FY25 · 3 Feb 2025		Q3 FY25Q1 FY27:Q1 consolidated organic growth was 12.4%. While management maintains its ~25% FY27 growth guidance, the quarterly performance is well below the 'new normal' run-rate.
Call transcript, Q1 FY27 · 10 Aug 2026		At Risk

Source: Inve Guidance Tracker for Poly Medicure Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Poly Medicure Limited's 30 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 27 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,470 +1.84% · +₹26.5

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −23.5% 1Y

₹1.2k₹1.4k₹1.6k₹1.8k₹2.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 10 Nov 2025Q3 FY26 — 6 Feb 2026Q4 FY26 — 25 May 2026Q1 FY27 — 10 Aug 2026

1Y: ₹1,922 on 24 Oct 2025 → ₹1,470. High ₹2,063.4 (11 Nov 2025), low ₹1,191.1 (30 Mar 2026).

Previous close
₹1,443.5
Market cap
₹14.9k Cr
52-week range
₹1,191.1 – ₹2,063.4
One year
−22.71%
Price to earnings (TTM to Jun 2026)
46.46×
Return on equity (TTM to Jun 2026)
10.90%

Overview

Symbol
NSE:POLYMED
Exchange
NSE
Currency
INR

What Poly Medicure Limited does

Based on the company's own presentations, annual report and earnings calls.

Poly Medicure (Polymed) manufactures and exports disposable and durable medical devices — IV cannulas and infusion sets, dialysis products and machines, critical-care/ICU consumables, cardiology catheters and stents, and orthopaedic fixation systems — across therapeutic areas including anaesthesia, oncology, urology and gastroenterology. It earns revenue by selling these devices through its own direct sales force and a global distributor network, with in-house tooling, automation and sterilization built into its manufacturing base. The company has moved up the technology curve over time, adding Renal Care (2018), Critical Care (2019), Cardiology (2024) and Orthopaedics (2025) on top of its founding Infusion Therapy business, the last two built via the acquisitions of PendraCare (Netherlands, cardiology catheters), Citieffe (Italy, orthopaedic fixation) and Medyneo (Brazil).

Segments

  • Infusion Therapy
  • Renal
  • Others
Manufacturing plants
15 plants across 5 countries (2 more under construction in India)
Countries with sales presence
125+
Installed device manufacturing capacity
1.8 billion+ devices per year
Product portfolio
225+ medical devices across 13 clinical specialities
Distributor network
1,000+ distributors across India and globally
Direct sales force
570+ sales associates in India, the US, Italy and Mexico
Founded 1995Headquarters New Delhi, India Company website

How the price took the results

close before → close after

Q1 FY27
+4.6%
10 Aug
Q4 FY26
−3.2%
25 May
Q3 FY26
−7.5%
6 Feb
Q2 FY26
−1.7%
10 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Poly Medicure Limited

Free account: one company. Everything above stays public.

Write why you follow Poly Medicure Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Poly Medicure Limited

Guides on how to read this kind of business and the numbers that matter.